The agreement also grants intellectual property rights of Siemens’ Patent No 7,650,888, titled ‘Method and System for Identification of a Medical Implant’ using RFID (radio frequency identification) to PositiveID.
The Wireless Body platform is designed to enhance wellness and disease management, for diabetes and other chronic illnesses by allowing healthcare systems to communicate with each other and monitor patients.
PositiveID chairman and CEO Scott Silverman said that they are excited for this opportunity to work together with Siemens and employ their patented technology to rapidly develop our Wireless Body platform.
"We believe that we are well positioned as a next generation leader in mobile health and personalized sensor tools, with the ability to wirelessly monitor patients, their vital signs and their medical devices via The Wireless Body," Silverman said.
In addition, the platform has the ability to identify medical devices, currently catheter ports, to allow them to communicate with an external reader to ensure proper medication dosages and safety for the patient.
